Dr. Elizabeth Volkmann is the Director of the UCLA Scleroderma Program and the founder and Co-Director of the UCLA Connective Tissue Disease-Related Interstitial Lung Disease (CTD-ILD) Program. She is an internationally recognized expert in systemic sclerosis and connective tissue disease-related interstitial lung disease.
Board-certified in both Internal Medicine and Rheumatology, Dr. Volkmann graduated from Pomona College where she majored in Neuroscience and minored in Dance. She received her medical degree from UCLA David Geffen School of Medicine, and subsequently completed her residency in Internal Medicine and fellowship in Rheumatology at UCLA. During her fellowship, she participated in the Specialty Training and Advanced Research (STAR) Program and earned her Master of Science degree in Clinical Research.
Dr. Volkmann cares deeply about the welfare of her patients and seeks to empower them on their healing journey with traditional, as well as holistic treatment approaches. She works closely with other specialists to develop comprehensive and personalized care plans that are unique for each patient.
Dr. Volkmann is also an active clinical and translational researcher in systemic sclerosis and interstitial lung disease. Her research focuses on discovering novel biomarkers that can be used to predict whether someone will improve on a specific therapy. She led the first study to investigate the gut microbiome in patients with systemic sclerosis and now leads an international consortium of investigators dedicated to understanding how the gut microbiome contributes to inflammation and clinical symptoms in patients with systemic sclerosis. She also participates in clinical trials to help identify new therapies for patients with autoimmune diseases.
She enjoys being active in nature (running, hiking, swimming, riding horses), and she loves to travel, dance and spend time with her family and friends.
Medical Board Certifications
Areas of Focus
- Systemic Sclerosis
- Autoimmune Diseases Associated with Interstitial Lung Disease
- Pulmonary Hypertension
Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. The Lancet 2023;401:304-318.
Volkmann ER, Wilhalme H, Assassi S, Kim G, Goldin J, Kuwana M, Tashkin DP, Roth MD. A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression. ACR Open Rheumatology 2023 [Online ahead of print].
Volkmann ER, Tashkin DP, Silver R, et al. Sex differences in biologic profiles and clinical outcomes in two randomized controlled trials for systemic sclerosis-related interstitial lung disease. Lancet Rheumatology 2022;4:E668-78.
Volkmann ER, Tashkin DP, Roth MD, et al. Early radiographic progression of scleroderma lung disease predicts long-term mortality. Chest 2022;161:1310-9.
- Volkmann ER, Steen VD, Li N, Roth MD, et al. Racial disparities in systemic sclerosis: Short- and long-term morbidity and mortality outcomes of African American participants of SLS I and II. ACR Open Rheumatology 2020;3:8-16.
- Volkmann ER, Tashkin DP, Sim M, et al. Early progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of Rheumatic Diseases 2019;78:122-30.
- Volkmann ER, Tashkin DP, Kuwana M, et al. Progression of interstitial lung disease in systemic sclerosis: The importance of pneumoproteins KL-6 and CCL-18. Arthritis and Rheumatology 2019;71:2059-67.
- Volkmann ER, Varga J. Emerging treatments for systemic sclerosis. Nature Rev Rheumatology 2019;15:208-24.
- Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate versus placebo for patients with systemic sclerosis-related interstitial lung disease. Arthritis and Rheumatol 2017;69:1451-60.
- Volkmann ER, Hoffmann-Vold A-M, Chang Y-L, et al. The systemic sclerosis disease state is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Gastroenterology 2017;4e000134.
In the News
- ReachMD - Elizabeth Volkmann, MD, MS
- Interstitial Lung Disease in Systemic Sclerosis With a Focus on Chest CT (Insights in ILD)
- Nutrition in Systemic Sclerosis (SRFCURE)
- Interstitial Lung Disease in Connective Tissue Disease: Existing and Emerging Therapies (Online Symposia)
- Exclusive interview: Elizabeth Volkmann on systemic sclerosis and colonic microbial consortium (UCLA Microbiome Center)
- Diet & Disaster: The Role of Nutrition in Systemic Sclerosis (WeAreSRUK)
- insightsinild.com/expert-videos/systemic-sclerosis-associated-lung-disease/ (Insights in ILD)
- New Biomarkers May Predict Interstitial Lung Disease Progression in Patients With Systemic Sclerosis (Medscape, June 2021)
- Elizabeth Volkmann, MD, on the Gut Microbiome in Systemic Sclerosis (HMP Global Learning Network, May 2021)
- 'Multidisciplinary approach' strongly encouraged in systemic sclerosis (Healio, October 2020)
- Short-term lung function better predicts mortality risk in SSc (MDedge, November 2018)
- Study suggests link between imbalanced gut microbiome and systemic sclerosis (UCLA Newsroom, May 2017)
- First gut microbiota alterations described in systemic sclerosis patients (PM360, June 2015)
*Note: News website links may expire without notice.
- Southern California Rising Stars, Super Doctors®, 2019-2023
- Doctor of the Year, National Scleroderma Foudation, 2022
- Top Doctors, Los Angeles Magazine, 2021
- Edith Busch-Stiftung Award in Rheumatology, 2020